Truist Financial Corp Has $402,000 Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Truist Financial Corp decreased its holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 3.2% in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 9,791 shares of the biopharmaceutical company’s stock after selling 319 shares during the quarter. Truist Financial Corp’s holdings in Ultragenyx Pharmaceutical were worth $402,000 as of its most recent filing with the SEC.

Other hedge funds also recently made changes to their positions in the company. BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its holdings in shares of Ultragenyx Pharmaceutical by 513.8% in the 1st quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 507,095 shares of the biopharmaceutical company’s stock worth $23,677,000 after purchasing an additional 424,476 shares during the last quarter. Clearbridge Investments LLC grew its holdings in shares of Ultragenyx Pharmaceutical by 0.7% in the 1st quarter. Clearbridge Investments LLC now owns 2,400,854 shares of the biopharmaceutical company’s stock worth $112,096,000 after purchasing an additional 17,362 shares during the last quarter. Price T Rowe Associates Inc. MD grew its holdings in shares of Ultragenyx Pharmaceutical by 3.5% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,568,873 shares of the biopharmaceutical company’s stock worth $166,632,000 after purchasing an additional 120,175 shares during the last quarter. Susquehanna Fundamental Investments LLC bought a new stake in shares of Ultragenyx Pharmaceutical in the 1st quarter worth about $1,074,000. Finally, Vanguard Group Inc. grew its holdings in shares of Ultragenyx Pharmaceutical by 19.9% in the 4th quarter. Vanguard Group Inc. now owns 8,673,432 shares of the biopharmaceutical company’s stock worth $414,764,000 after purchasing an additional 1,440,264 shares during the last quarter. Institutional investors and hedge funds own 97.67% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the stock. Wedbush upped their target price on shares of Ultragenyx Pharmaceutical from $43.00 to $46.00 and gave the stock a “neutral” rating in a report on Friday, August 2nd. Royal Bank of Canada reissued an “outperform” rating and set a $77.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Thursday, September 26th. The Goldman Sachs Group increased their price objective on shares of Ultragenyx Pharmaceutical from $67.00 to $76.00 and gave the stock a “buy” rating in a report on Friday, August 2nd. Wells Fargo & Company raised their target price on shares of Ultragenyx Pharmaceutical from $72.00 to $75.00 and gave the company an “overweight” rating in a research note on Friday, August 2nd. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $116.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, October 1st. Two investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $87.43.

Insider Activity

In other news, CEO Emil D. Kakkis sold 20,000 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $55.85, for a total value of $1,117,000.00. Following the sale, the chief executive officer now directly owns 2,223,985 shares in the company, valued at $124,209,562.25. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other news, CEO Emil D. Kakkis sold 20,000 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $55.85, for a total value of $1,117,000.00. Following the sale, the chief executive officer now directly owns 2,223,985 shares in the company, valued at $124,209,562.25. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Howard Horn sold 7,465 shares of the firm’s stock in a transaction on Thursday, October 10th. The shares were sold at an average price of $52.76, for a total transaction of $393,853.40. Following the completion of the transaction, the chief financial officer now directly owns 92,301 shares of the company’s stock, valued at $4,869,800.76. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 47,556 shares of company stock worth $2,519,367 over the last ninety days. Insiders own 5.80% of the company’s stock.

Ultragenyx Pharmaceutical Stock Performance

Shares of RARE stock opened at $56.77 on Friday. The company has a market capitalization of $4.72 billion, a P/E ratio of -7.07 and a beta of 0.57. The company’s 50 day moving average price is $55.65 and its two-hundred day moving average price is $47.50. Ultragenyx Pharmaceutical Inc. has a 52 week low of $31.52 and a 52 week high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($1.52) EPS for the quarter, topping the consensus estimate of ($1.64) by $0.12. The firm had revenue of $147.03 million for the quarter, compared to the consensus estimate of $123.20 million. Ultragenyx Pharmaceutical had a negative net margin of 121.57% and a negative return on equity of 266.02%. The business’s quarterly revenue was up 35.7% on a year-over-year basis. During the same period last year, the company posted ($2.25) EPS. Analysts forecast that Ultragenyx Pharmaceutical Inc. will post -6.24 earnings per share for the current year.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.